Novartis
(milbemycin oxime - lufenuron)
Caution
Federal (USA) law restricts this drug to use by or on the
order of a licensed veterinarian.
Warnings: Not for human use. Keep this
and all drugs out of the reach of children.
The palatable once-a-month prescription tablet that prevents
heartworm disease and flea populations in dogs and puppies. SENTINEL®
Flavor Tabs® also control flea populations
and adult hookworms, and remove and control adult roundworm and whipworm
infections in dogs and puppies.
Description
SENTINEL Flavor Tabs are available in four tablet sizes in
color-coded packages for oral administration to dogs and puppies according
to their weight. (See Dosage Section). Each tablet is formulated to provide
a minimum of 0.23 mg/pound (0.5 mg/kg) of milbemycin oxime and 4.55 mg/pound
(10 mg/kg) body weight of lufenuron.
Milbemycin oxime consists of the oxime derivatives of
5-didehydromilbemycins in the ratio of approximately 80% A4
(C32H45NO7,
MW 555.71) and 20% A3 (C31H43NO7,
MW 541.68). Milbemycin oxime is classified as a macrocyclic anthelmintic.
Lufenuron is a benzoylphenylurea derivative with the
following chemical composition: N-[2,5-dichloro-4-(1,1,2,3,3,3, -
hexafluoropropoxy)-phenylaminocarbonyl]-2,6- difluorobenzamide (C17H8Cl2F8N2O3,
MW 511.15). Benzoylphenylurea compounds, including lufenuron, are classified
as insect development inhibitors (IDIs).
Mode of Action
Milbemycin oxime, one active ingredient in SENTINEL Flavor
Tabs, is a macrocyclic anthelmintic which is believed to act by interfering
with invertebrate neurotransmission. Milbemycin oxime eliminates the tissue
stage of heartworm larvae and the adult stage of hookworm
(Ancylostoma caninum), roundworm
(Toxocara canis and Toxascaris
leonina) and whipworm (Trichuris vulpis)
infestations when administered orally according to the recommended dosage
schedule.
Lufenuron, the other active ingredient in SENTINEL Flavor
Tabs, is an insect development inhibitor which breaks the flea life cycle by
inhibiting egg development. Lufenuron's mode of action is interference with
chitin synthesis, polymerization and deposition. Lufenuron has no effect on
the adult flea. After biting a lufenuron-treated dog, the female flea
ingests a blood meal containing lufenuron which is subsequently deposited in
her eggs. Lufenuron prevents most flea eggs from hatching or maturing into
adults and thus prevents and controls flea populations by breaking the life
cycle (See Efficacy).
Indications
SENTINEL Flavor Tabs are indicated for use in dogs and
puppies, four weeks of age and older, and two pounds body weight or greater.
SENTINEL Flavor Tabs are also indicated for the prevention of heartworm
disease caused by Dirofilaria immitis, for the
prevention and control of flea populations, the control of adult
Ancylostoma caninum (hookworm), and the removal and
control of adult Toxocara canis and
Toxascaris leonina (roundworm) and
Trichuris vulpis (whipworm) infections.
Lufenuron controls flea populations by preventing the
development of flea eggs and does not kill adult fleas. Concurrent use of an
adulticide product may be necessary for adequate control of adult fleas.
SENTINEL Flavor Tabs may be used concurrently with CAPSTAR®
(nitenpyram) Tablets to provide a Flea Management System that kills adult
fleas and prevents flea eggs from hatching. Please see the Supplemental
Package Insert provided with this product for information about concurrent
use of the two products.
Without concurrent use of an adulticide,
adequate flea control may not be achieved in dogs that have repeated
exposure to flea infected animals or environments.
Precautions
Do not use in puppies less than four weeks of age and less
than two pounds of body weight. Prior to administration of SENTINEL Flavor
Tabs, dogs should be tested for existing heartworm infections. Infected dogs
should be treated to remove adult heartworms and microfilariae prior to
initiating treatment with SENTINEL Flavor Tabs. Mild, transient
hypersensitivity reactions manifested as labored respiration, vomiting,
salivation and lethargy have been noted in some treated dogs carrying a high
number of circulating microfilariae. These reactions are presumably caused
by release of protein from dead or dying microfilariae.
SENTINEL Flavor Tabs immediately break the flea life cycle
by inhibiting egg development. However, pre-existing flea populations may
continue to develop and emerge after treatment with SENTINEL Flavor Tabs has
begun. Based on results of clinical studies, this emergence generally occurs
during the first 30-60 days. Therefore, noticeable control may not be
observed until several weeks after dosing when a pre-existing infestation is
present. Cooler geographic areas may have longer lag periods due to a
prolonged flea life cycle. The concurrent use of an approved adulticide,
like CAPSTAR may be employed depending on the severity of the infestation.
If a SENTINEL Flavor Tabs-treated dog comes in contact with
a flea-infested environment, adult fleas may infest the treated animal.
These adult fleas are unable to produce viable offspring. The temporary use
of an adulticide product may be necessary to kill these adult fleas.
Efficacy: Milbemycin Oxime
Milbemycin oxime provided complete protection against
heartworm infection in both controlled laboratory and clinical trials.
In laboratory studies, a single dose of milbemycin oxime at
0.5 mg/kg was effective in removing roundworm, hookworm and whipworm. In
well-controlled clinical trials, milbemycin oxime was also effective in
removing roundworms and whipworms and in controlling hookworms.
Efficacy: Lufenuron
Lufenuron provided 99% control of flea egg development for
32 days following a single dose of lufenuron at 10 mg/kg in studies using
experimental flea infestations. In well-controlled clinical trials, when
treatment with lufenuron tablets was initiated prior to the flea season,
mean flea counts were lower in lufenuron-treated dogs versus placebo-treated
dogs. After 6 monthly treatments, the mean number of fleas on lufenuron-treated
dogs was approximately 4 compared to 230 on placebo-treated dogs.
When treatment was initiated during the flea season,
lufenuron tablets were effective in controlling flea infestations on dogs
that completed the study. The mean flea count per lufenuron-treated dog was
approximately 74 prior to treatment but had decreased to 4 after six monthly
doses of lufenuron. A topical adulticide was used in the first eight weeks
of the study to kill the pre-existing adult fleas.
Safety: Milbemycin Oxime
Milbemycin oxime has been tested safely in over 75 different
breeds of dogs, including collies, pregnant females, breeding males and
females, and puppies over two weeks of age. In well-controlled clinical
field studies 786 dogs completed treatment with milbemycin oxime. Milbemycin
oxime was used safely in animals receiving frequently used veterinary
products such as vaccines, anthelmintics, antibiotics, steroids, flea
collars, shampoos and dips.
Two studies in heartworm-infected dogs were conducted which
demonstrated mild, transient hypersensitivity reactions in treated dogs with
high microfilaremia counts (see Precautions for reactions observed). Safety
studies in pregnant dogs demonstrated that high doses (1.5 mg/kg = 3X) of
milbemycin oxime given in an exaggerated dosing regimen (daily from mating
through weaning), resulted in measurable concentrations of the drug in milk.
Puppies nursing these females which received exaggerated dosing regimens
demonstrated milbemycin-related effects. These effects were directly
attributable to the exaggerated experimental dosing regimen. The product is
normally intended for once-a-month administration only. Subsequent studies
included using 3X daily from mating to one week before weaning and
demonstrated no effects on the pregnant females or their litters. A second
study where pregnant females were dosed once at 3X the monthly use rate
either before, on the day of or shortly after whelping resulted in no
effects on the puppies.
Some nursing puppies, at 2, 4, and 6 weeks of age, given
greatly exaggerated oral doses of milbemycin oxime (9.6 mg/kg = 19X)
exhibited signs typified by tremors, vocalization and ataxia. These effects
were all transient and puppies returned to normal within 24 to 48 hours. No
effects were observed in puppies given the recommended dose of milbemycin
oxime (0.5 mg/kg). This product has not been tested in dogs less than 2.2
pounds in body weight.
A rising-dose safety study conducted in rough-coated collies
manifested a clinical reaction consisting of ataxia, pyrexia and periodic
recumbency in one of fourteen dogs treated with milbemycin oxime at 12.5
mg/kg (25X monthly use rate). Prior to receiving the 12.5 mg/kg dose (25X
monthly use rate) on day 56 of the study, all animals had undergone an
exaggerated dosing regimen consisting of 2.5 mg/kg milbemycin oxime (5X
monthly use rate) on day 0, followed by 5.0 mg/kg (10X monthly use rate) on
day 14 and 10.0 mg/kg (20X monthly use rate) on day 32. No adverse reactions
were observed in any of the collies treated with this regimen up through the
10.0 mg/kg (20X monthly use rate) dose.
Safety: Lufenuron
Lufenuron tablets have been used and tested safely in over
forty breeds of dogs, including pregnant females, breeding males and puppies
over six weeks of age. In well-controlled clinical trials, 151 dogs
completed treatment with lufenuron tablets. Lufenuron tablets were used
safely in animals receiving frequently used veterinary products such as
vaccines, anthelmintics, antibiotics and steroids. In a ten-month study,
doses up to 10X the recommended dose rate of 10 mg/kg caused no overt
toxicity. A single dose of 200 mg/kg (20X the recommended dose rate) had no
marked effect on adult dogs, but caused decreased activity and appetite in
eight week old puppies. Mean body weights of male and female puppies were
higher in treated versus control group at the end of the study. In
specifically designed target animal safety studies, lufenuron tablets were
tested with concurrent administration of flea adulticides containing
carbaryl, permethrin, chlorpyriphos and cythioate. No toxicity resulted from
these combinations. Lufenuron tablets did not cause cholinesterase
inhibition nor did they enhance cholinesterase inhibition caused by exposure
to organophosphates.
Four reproductive safety studies were conducted in breeding
dogs with lufenuron tablets: two laboratory and two well-controlled clinical
studies. In one of the laboratory studies, where lufenuron was administered
to beagle dogs at doses equivalent to 90X (3X daily) the monthly recommended
dose of 10 mg/kg, the ratio of gravid females to females mated was 8/8 or
100% in the control group and 6/9 or 67% in the lufenuron-treated group. The
mean number of pups per litter was two animals higher in the treated versus
control groups and the mean birth weights of pups from treated bitches in
this study was lower than control groups.
These pups grew at a similar rate to control pups. There was
a higher incidence of four clinical signs in the lufenuron-treated versus
control group: nasal discharge, pulmonary congestion, diarrhea/dehydration
and sluggishness. The incidence of these signs was transient and decreasing
by the end of lactation. Results from three additional reproductive safety
studies, one laboratory and two clinical field studies evaluating eleven
breeds of dogs, did not demonstrate any adverse findings for the
reproductive parameters measured including fertility, pup birth weights and
pup clinical signs after administration of lufenuron up to 5X the
recommended monthly use rate.
Data from analysis of milk from lactating animals treated
with lufenuron tablets at 2X and 6X the recommended monthly use rate
demonstrates that lufenuron concentrates in the milk of these dogs. The
average milk: blood concentration ratio was approximately 60 (i.e., 60X
higher drug concentrations in the milk compared to drug levels in the blood
of treated bitches). Nursing puppies averaged 8-9 times higher blood
concentrations of lufenuron compared to their dams.
Dosage
SENTINEL Flavor Tabs are given orally, once a month, at the
recommended minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime and
4.55 mg/lb (10 mg/kg) lufenuron.
|
Recommended Dosage Schedule |
|
Body Weight |
Milbemycin Oxime Per Tablet |
Lufenuron Per Tablet |
|
2 to 10 lbs. |
2.3 mg |
46.0 mg |
|
11 to 25 lbs. |
5.75 mg |
115 mg |
|
26 to 50 lbs. |
11.5 mg |
230 mg |
|
51 to 100 lbs. |
23.0 mg |
460 mg |
Dogs over 100 lbs are provided the appropriate combination
of tablets.
* Please see separate insert in this package
for concurrent dosing of SENTINEL Flavor Tabs and
CAPSTAR Tablets.
Administration: TO ENSURE ADEQUATE
ABSORPTION, ALWAYS ADMINISTER SENTINEL Flavor Tabs TO DOGS IMMEDIATELY AFTER
OR IN CONJUNCTION WITH A NORMAL MEAL.
SENTINEL Flavor Tabs are palatable and most dogs will
consume the tablet when offered by the owner. As an alternative to direct
dosing, the tablets can be hidden in food. Be certain the dog consumes the
entire tablet or tablets. Administer SENTINEL Flavor Tabs to dogs,
immediately after or in conjunction with a normal meal. Food is essential
for adequate absorption of lufenuron. Watch the dog closely following
administration to be sure the entire dose has been consumed. If it is not
entirely consumed, redose with the full recommended dose as soon as
possible.
SENTINEL Flavor Tabs must be administered monthly,
preferably on the same date each month. Treatment with SENTINEL Flavor Tabs
may begin at any time of year. In geographic areas where mosquitoes and
fleas are seasonal, the treatment schedule should begin one month prior to
the expected onset and should continue until the end of “mosquito and flea
season.” In areas with year-round infestations, treatment should continue
through the entire year without interruption.
If a dose is missed and a 30-day interval between dosing is
exceeded, administer SENTINEL Flavor Tabs immediately and resume the monthly
dosing schedule. If SENTINEL Flavor Tabs replace daily diethylcarbamazine
(DEC) for heartworm prevention, the first dose must be given within 30 days
after the last dose of DEC.
Adverse Reactions
The following adverse reactions have been reported in dogs
after giving milbemycin oxime or lufenuron: vomiting, depression/lethargy,
pruritus, urticaria, diarrhea, anorexia, skin congestion, ataxia,
convulsions, hypersalivation and weakness.
How Supplied: SENTINEL Flavor Tabs are
available in four tablet sizes, (see Dosage Section), formulated according
to the weight of the dog. Each tablet size is available in color-coded
packages of six and twelve tablets each, which are packaged 10 per display
carton.
Storage Conditions
Store in a dry place at controlled room temperature, between
59° and 86°F (15-30°C).
SENTINEL®
(MILBEMYCIN OXIME/LUFENURON) Flavor Tabs®
/ CAPSTAR® (NITENPYRAM)
FLEA MANAGEMENT SYSTEM
Supplemental Veterinary Package Insert
This insert describes the concurrent use of SENTINEL®
(milbemycin oxime/lufenuron) Flavor Tabs® and
CAPSTAR® (nitenpyram) Tablets for the
management of fleas on dogs and puppies. Please read the
insert contained in each package for complete information on the individual
products prior to dispensing or dosing. The effects of SENTINEL Flavor Tabs
on heartworm disease and internal parasites are not described in this
supplement.
Indications
In dogs and puppies, the concurrent use of SENTINEL Flavor
Tabs and CAPSTAR Tablets is indicated to kill adult fleas and prevent eggs
from hatching. The effects of SENTINEL Flavor Tabs, which prevent and
control flea populations, and CAPSTAR Tablets, which treat flea
infestations, are combined to provide a FLEA MANAGEMENT SYSTEM.
Step 1: Control
Give SENTINEL Flavor Tabs once per month to prevent and
control flea populations. SENTINEL Flavor Tabs contain lufenuron. Lufenuron
controls flea populations by preventing the development of flea eggs and
does not kill adult fleas. If a dog currently has a flea infestation, more
rapid relief can be accomplished by adding CAPSTAR to the treatment as
follows.
Step 2: Kill Adult Fleas
If your pet currently has a flea infestation, use CAPSTAR
Tablets to kill adult fleas. CAPSTAR Tablets contain nitenpyram and are
effective for the treatment of flea infestations. Nitenpyram starts killing
adult fleas within 30 minutes of administration.
Administer CAPSTAR Tablets once per week until adult fleas
are no longer observed.
For a severe flea infestation, administer CAPSTAR Tablets
twice per week until adult fleas are no longer observed.
Additional CAPSTAR Tablets may be administered as needed to
kill the occasional adult flea picked up from infested environments.
It is important to treat all cats and dogs in the household.
All cats should be treated with approved products like lufenuron in
combination with nitenpyram as needed. Fleas can reproduce on untreated pets
and allow infestations to persist.
Dosage
The combination of SENTINEL Flavor Tabs and CAPSTAR Tablets
should be administered according to the following schedule. Weigh your dog
prior to administration to ensure proper dosage. Do not administer to dogs
under 2 pounds.
|
Recommended Dosage Schedule |
|
Body Weight |
Dose |
CAPSTAR
Once or twice weekly
(Nitenpyram per tablet) |
SENTINEL Flavor Tabs
once per month
(Lufenuron per tablet) |
|
2 to 10 lbs. |
One Tablet |
11.4 mg |
46 mg |
|
11 to 25 lbs. |
One Tablet |
11.4 mg |
115 mg |
|
26 to 50 lbs. |
One Tablet |
57.0 mg |
230 mg |
|
51 to 100 lbs. |
One Tablet |
57.0 mg |
460 mg |
|
101 to 125 lbs. |
One Tablet |
57.0 mg |
** |
* If adult fleas are seen
**Dogs over 100 lbs. are provided the
appropriate combination of SENTINEL
Flavor Tabs.
Precautions
The safety of the concurrent use of SENTINEL Flavor Tabs and
CAPSTAR Tablets in pregnant or nursing dogs or in puppies less than 11 weeks
of age has not been demonstrated.
Adverse Reactions
The following adverse reactions have been reported in dogs
after giving SENTINEL Flavor Tabs: vomiting, depression/lethargy, pruritus,
urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions,
hypersalivation and weakness.
Effectiveness
Please refer to the labeling for SENTINEL Flavor Tabs and
CAPSTAR Tablets for information about the effectiveness of each product.
Studies testing the concurrent use of the two products demonstrated that
each product remains effective for its labeled indication when both are
administered concurrently. In a simulated home environment, the
administration of SENTINEL Flavor Tabs monthly and CAPSTAR either once or
twice weekly demonstrated a greater and more rapid reduction of established
flea infestations than SENTINEL Flavor Tabs alone.
Animal Safety
The combination of nitenpyram, milbemycin oxime and
lufenuron has been tested in a 90 day laboratory study. Administration of 5X
the recommended use rate of CAPSTAR Tablets for 90 consecutive days,
concurrently with administration of 5X the recommended use rate of SENTINEL
Flavor Tabs every 2 weeks for 7 treatments was well tolerated.
Flea Infestations on Dogs
In addition to the common nuisance irritations associated
with infestations, fleas can be responsible for skin conditions in the dog
such as flea allergy dermatitis. Fleas also transmit other parasites,
including tapeworms. The control of flea infestations reduces the problems
associated with these parasites.
SENTINEL Flavor Tabs break the flea life cycle by inhibiting
egg development. CAPSTAR Tablets rapidly kill adult fleas on the dog. The
concurrent use of these two products provides an effective flea management
system
The following diagram illustrates the flea's life cycle and
where the combination of SENTINEL Flavor Tabs and CAPSTAR Tablets work:
Life Cycle of the Flea
A single female flea may produce up to 2,000 eggs over
her lifetime. Eggs hatch and can develop into adults within only three
weeks. Adult female fleas feed by ingesting blood from the pet and
subsequently lay eggs, which drop off the pet's coat. Within days,
larvae hatch from the eggs and live undetected in the pet's
surroundings, such as the carpet and bedding. Flea larvae spin a cocoon,
and, when appropriately stimulated, a young adult flea emerges and jumps
onto the pet to continue the life cycle.